Bellwether Advisors’s Vir Biotechnology VIR Stock Holding History

Bellwether Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-98	Closed	-$4K	–	626
2021 Q2	$4K	Buy	+98	New	+$4.46K	﹤0.01%	347

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellwether Advisors's VIR Position: Q3 2021 in Review

Bellwether Advisors sold out of Vir Biotechnology (VIR) in Q3 2021, closing a stake of 98 shares — an estimated $4K sold.

Bellwether Advisors first reported a position in VIR in Q2 2021 and held it in 1 quarter. The position peaked at $4K in Q2 2021. 175 funds tracked by Wall St. Rank hold VIR as of Q3 2021.

Bellwether Advisors reported no remaining Vir Biotechnology position as of Q3 2021 after selling out during the quarter.
Bellwether Advisors sold 98 Vir Biotechnology shares in Q3 2021, an estimated $4K.
Bellwether Advisors first reported a position in Vir Biotechnology in Q2 2021 and held it in 1 quarter.
Bellwether Advisors's Vir Biotechnology position peaked at $4K in Q2 2021.
175 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2021.

Based on Bellwether Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.